Hereditary ATTR Val122Ile Cardiac Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Hereditary ATTR Val122Ile Cardiac Amyloidosis

key information

source: University College London

year: N/A

summary/abstract:

Hereditary ATTR amyloidosis is an inherited genetic disease in which there is thickening and stiffening of the heart muscle, due to a build-up of abnormal protein. This abnormal protein may also build up in the carpal tunnels in the wrists and in the lower back known as the lumbar canal. Most patients are at least 60 years of age. 

This condition is more common in men than in women, and is particularly common in people of Afro-Caribbean or African American ancestry, about one in twenty of whom possess the gene that predisposes them to developing this condition.

Until recently many people with ATTR amyloid affecting the heart were misdiagnosed as having heart disease due to other more common causes, such as high blood pressure or ischaemic heart disease. Hereditary ATTR amyloidosis (the most commonly recognised form of hereditary systemic amyloidosis worldwide) was traditionally referred to as familial amyloid polyneuropathy (FAP), when disease mainly affected the nerves, or familial amyloid cardiomyopathy (FAC), when disease mainly affected the heart. 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close